Analyst consensus rating
GRI Bio Analyst Rating: Strong Buy
Direct answer
GRI Bio's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.50.
Forecast evidence checked September 4, 2026.
Get free GRI Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.99
- Average price target
- $18.50
- High price target
- $27.00
- Low price target
- $10.00
- Low target gap
- +234.6%
- Target upside
- +519%
- High target gap
- +803.4%
- Target range width
- 568.8%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for GRI Bio?
GRI Bio has a verified Strong Buy consensus. The same dataset has an average price target of $18.50.
How far are GRI Bio's low and high targets from the recorded price?
The low target implies +234.6%, while the high target implies +803.4%.
How many analysts are included in GRI Bio's consensus?
The verified consensus includes 2 analysts.
How is GRI Bio's target upside or downside calculated?
The average target of $18.50 is divided by the recorded price of $2.99, then one is subtracted to produce +519%. This does not guarantee a future return.
When was GRI Bio's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.